FDA Shares Biosimilar Progress and Seeks Input at Public Meeting
Published Date: 8/15/2025
Notice
Summary
The FDA is hosting a public meeting to share progress on their Biosimilar User Fee Act III program, which helps speed up the development of biosimilar medicines. This program supports companies making affordable alternatives to brand-name biologic drugs, aiming to make these medicines easier and faster to bring to patients between 2023 and 2027. They’re also asking for ideas on what research to focus on next to keep improving the process.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA pilot speeds biosimilar development
The FDA launched a BsUFA III regulatory science pilot to help speed development of biosimilar medicines and support companies making affordable alternatives to brand-name biologic drugs between 2023 and 2027. The pilot focuses on advancing interchangeable products and improving development efficiency to help firms bring biosimilars to market faster.
Potential faster access to cheaper biologics
The BsUFA III program aims to make biosimilar and interchangeable medicines easier and faster to bring to patients between 2023 and 2027. By advancing interchangeability and improving development efficiency, the program is intended to support availability of more affordable biologic treatment options for patients.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in